

## PHARMANUTRA S.P.A.: NOTICE OF CALL FOR ORDINARY SHAREHOLDERS' MEETING PUBLISHED

*Pisa, 9<sup>th</sup> April 2020* – PharmaNutra S.p.A. (the “**Company**”) hereby notifies the call for the ordinary Shareholders’ Meeting to be held in the offices of the Notary Jacopo Sodi, in Via delle Mantellate n. 9, Florence, for 27<sup>th</sup> April 2020, at 15:00 in first call and, if required, 28<sup>th</sup> April 2020, in second call, same place and time, with the following proposals on the agenda:

1. *Financial Statements for the fiscal year of PharmaNutra S.p.A. as at 31<sup>st</sup> December 2019 and allocation of profit for the year.*
  - 1.1. *Approval of the Financial Statements for the fiscal year as at 31<sup>st</sup> December 2019, after examining the reports from the Auditing Firm and the Board of Statutory Auditors. Presentation of the Consolidated Financial Statements as at 31<sup>st</sup> December 2019 of the PharmaNutra Group. Resolutions pertaining thereto and resulting therefrom.*
  - 1.2. *Allocation of profit for the year. Resolutions pertaining thereto and resulting therefrom.*
2. *Appointment of the Board of Directors.*
  - 2.1. *Decision on number of members.*
  - 2.2. *Appointment of Directors.*
  - 2.3. *Decision on duration of office.*
  - 2.4. *Decision on fees.*
3. *Proposal to authorise the purchase and disposal of treasury stock pursuant to arts. 2357 and 2357-ter of the Italian civil code, and art. 132 of Legislative Decree 58/1998 and relative implementation provisions. Resolutions pertaining thereto and resulting therefrom.*

The notice calling the ordinary Shareholders’ Meeting was published in the daily newspaper “MF – Milano Finanza” of 9<sup>th</sup> April 2020 and on the *company* website ([www.pharmanutra.it](http://www.pharmanutra.it), “*Section Investor Relations – Corporate – Shareholders’ Meetings*”).

Please note that pursuant to art. 106 of Decree Law no. 18 of 17<sup>th</sup> March 2020, those with the right to vote may **only** take part in the Shareholders’ Meeting through Società per Amministrazioni Fiduciarie “SPAFID” S.p.A., representing the shareholders designated by the Company pursuant to art. 135-*undecies* Legislative Decree 58/1998 and the aforementioned decree (the “**Designated Representative**”). For further information on how to take part in the Shareholders’ Meeting and assign proxies or sub-proxies to the Designated Representative, please refer to the notice of call.

Please note that the following will be made available to the public, within terms established by law, on the Company *website* ([www.pharmanutra.it](http://www.pharmanutra.it), “*Section Investor Relations – Corporate – Shareholders’*”).

*Meetings*"): (i) the forms to be used to assign proxies to the Designated Representative; (ii) the reports by the Board of Directors illustrating each item on the Meeting agenda; (iii) the draft financial statements for the year as at 31<sup>st</sup> December 2019, together with legal documentation; and (iv) the consolidated financial statements as at 31<sup>st</sup> December 2019.

**PharmaNutra S.p.A.**

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 112 studies published involving more than 7000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

For information:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b  
56122 Pisa  
Tel. +39 050 7846500  
[investorrelation@pharmanutra.it](mailto:investorrelation@pharmanutra.it)  
Internal Press Office  
[press@calabughi.com](mailto:press@calabughi.com)

**Nomad  
CFO SIM S.p.A.**

Via dell'Annunciata, 23/4  
20121 Milan  
Tel. +39 02 303431  
[ecm@cfosim.com](mailto:ecm@cfosim.com)

**Press Office  
Spriano Communication & Partners**

Via Santa Radegonda, 16  
20121 Milan  
Tel. +39 02 83635708  
  
Matteo Russo  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
Cristina Tronconi  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)